The main conclusions include: the identification of metabolic-microenvironmental regulatory axes centered on PHGDH and VEGFA; the classification of CRC into two molecular subtypes with different therapeutic sensitivities, which provides a potential strategy for targeted metabolism in combination with antivascular therapies; and the construction of a columnar graph model that significantly optimizes prognosis prediction of patients with CRC, which is particularly valuable in individualized survival assessment of patients with advanced disease. The gene discussed is PHGDH; the disease is colorectal carcinoma.